Welcome!

News Feed Item

Vaccine Industry Watchdog Responds to Forbes' Defense of Mercury-Laced Vaccinations

Dr. Brian Hooker, PhD, says Forbes misrepresented congressional record and CDC studies

CHARLOTTE, N.C., Feb. 28, 2014 /PRNewswire-iReach/ -- Last week, PhD biochemist Brian Hooker created a stir when he announced he had obtained sensitive documents from the CDC (Centers for Disease Control and Prevention) through Freedom of Information Act (FOIA) requests. According to Hooker, these documents implicated the vaccine preservative Thimerosal (50% mercury by weight) in causing autism and other neurodevelopmental disorders, revealing what he says CDC officials had long known, but never disclosed publicly: a 7.6-fold increase in autism during infancy after exposure. Emily Willingham, who frequently editorializes in support of the vaccine program, responded in Forbes by criticizing a news story that went viral on the subject of Dr. Hooker's FOIA revelations.

(Photo: http://photos.prnewswire.com/prnh/20140228/MN73622)

Dr. Hooker methodically itemized "misrepresentations and outright errors" that he says appeared in Forbes.com. "Willingham either confused two CDC studies or intentionally deceived Forbes' readers," said Hooker. "There was one concealed study that found a very high association between Thimerosal and autism. That was the study that was kept from the public which I obtained. And there was a later study by the same researcher – CDC-paid epidemiologist Thomas Verstraeten – who had watered down the results of the earlier study to appear as if there were no association between Thimerosal and autism. That second study was made public even though it was fraudulent.  Willingham pointed to the conclusions of the later study and implied that they came from the earlier study."

Although Willingham denies that the CDC researcher, Dr. Verstraeten, was under pressure to alter the results of the earlier study, Dr. Hooker points out that Verstraeten's own email written at the time (an internal CDC document obtained through FOIA) reveals otherwise. Verstraeten's subject line, "It just won't go away," refers to his difficulty in making the statistical association between Thimerosal and autism disappear.

Making an example of how he says Dr. Verstraeten hid that association in his reanalysis of the data on 400,000 infants, Dr. Hooker says Verstraeten did not include clinics within HMOs where there was a strong correlation between Thimerosal exposure and autism incidence. According to Hooker, "Willingham brazenly disregarded Verstraeten's own chilling words: 'All the harm is done in the first month [of life]…' He wrote those words about the study I obtained."  The abstracts of Verstraeten's two studies and further comment on the controversy can be viewed here.

Dr. Hooker says Willingham misrepresented the congressional record when she selected quotes from a 2007 U.S. Senate report which falsely asserted that allegations of a cover-up are unsubstantiated. He considers the U.S. House of Representatives' 2003 report titled Mercury in Medicine (the result of a 3-year investigation) a "scathing, 80-page indictment of the CDC regarding the Thimerosal coverup."  The report concludes, "Our public health agencies' failure to act is indicative of institutional malfeasance for self-protection and misplaced protectionism of the pharmaceutical industry."

Willingham treated Verstraeten's final, watered-down results as solid epidemiological evidence, when, according to Hooker, the final version of the Verstraeten study is fraught with statistical flaws, primarily "overmatching." He provided an example:  the cases and controls received the same vaccination schedule and the same Thimerosal dosage; thus, no true comparison could be made.  Hooker says this invalidates all of the analyses (done separately for HMOs A, B and C).

Willingham quoted Verstraeten's  2004 letter in the journal Pediatrics regarding his later, diluted study, omitting the fact that the CDC has used the study to exonerate Thimerosal despite Verstraeten calling the study "neutral."  In addition, the 2004 Institute of Medicine (IOM) Immunization Safety Review (ISR) committee report used this as the only U.S. epidemiological study (among the 5 studies) as the basis to reject the Thimerosal-autism hypothesis, shutting the door on any further research. 

"In light of Ms. Willingham's enthusiastic defense of mercury in vaccines despite conclusive evidence of its harm to children, it is ironic that the tagline for her column is 'I write about the science they are selling you.'" remarked Dr. Hooker. Thimerosal is still administered to pregnant women and infants via the flu shot.

Brian Hooker, PhD, PE is an associate professor of biology at Simpson University. His over 50 science and engineering papers have been published in internationally recognized, peer-reviewed journals. He has a son, aged 16, who developed normally but then regressed into autism after receiving Thimerosal-containing vaccines. Dr. Brian Hooker's investigative research is sponsored by the Focus Autism Foundation, which is dedicated to informing the public about the cause(s) of the autism epidemic and the rise of chronic illnesses. To learn more, visit focusautisminc.org and ashotoftruth.org,  an educational website sponsored by Focus Autism. 

AutismOne is co-sponsoring this message and is a non-profit 501(c)(3) organization that provides education and supports advocacy efforts for children and families touched by an autism diagnosis. To learn more, visit autismone.org.

Media Contact: Angela Medlin, A Shot of Truth, 1 866-498-2768, [email protected]

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE Brian Hooker, PhD, PE

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
With more than 30 Kubernetes solutions in the marketplace, it's tempting to think Kubernetes and the vendor ecosystem has solved the problem of operationalizing containers at scale or of automatically managing the elasticity of the underlying infrastructure that these solutions need to be truly scalable. Far from it. There are at least six major pain points that companies experience when they try to deploy and run Kubernetes in their complex environments. In this presentation, the speaker will d...
While DevOps most critically and famously fosters collaboration, communication, and integration through cultural change, culture is more of an output than an input. In order to actively drive cultural evolution, organizations must make substantial organizational and process changes, and adopt new technologies, to encourage a DevOps culture. Moderated by Andi Mann, panelists discussed how to balance these three pillars of DevOps, where to focus attention (and resources), where organizations might...
The deluge of IoT sensor data collected from connected devices and the powerful AI required to make that data actionable are giving rise to a hybrid ecosystem in which cloud, on-prem and edge processes become interweaved. Attendees will learn how emerging composable infrastructure solutions deliver the adaptive architecture needed to manage this new data reality. Machine learning algorithms can better anticipate data storms and automate resources to support surges, including fully scalable GPU-c...
When building large, cloud-based applications that operate at a high scale, it's important to maintain a high availability and resilience to failures. In order to do that, you must be tolerant of failures, even in light of failures in other areas of your application. "Fly two mistakes high" is an old adage in the radio control airplane hobby. It means, fly high enough so that if you make a mistake, you can continue flying with room to still make mistakes. In his session at 18th Cloud Expo, Le...
Machine learning has taken residence at our cities' cores and now we can finally have "smart cities." Cities are a collection of buildings made to provide the structure and safety necessary for people to function, create and survive. Buildings are a pool of ever-changing performance data from large automated systems such as heating and cooling to the people that live and work within them. Through machine learning, buildings can optimize performance, reduce costs, and improve occupant comfort by ...
As Cybric's Chief Technology Officer, Mike D. Kail is responsible for the strategic vision and technical direction of the platform. Prior to founding Cybric, Mike was Yahoo's CIO and SVP of Infrastructure, where he led the IT and Data Center functions for the company. He has more than 24 years of IT Operations experience with a focus on highly-scalable architectures.
The explosion of new web/cloud/IoT-based applications and the data they generate are transforming our world right before our eyes. In this rush to adopt these new technologies, organizations are often ignoring fundamental questions concerning who owns the data and failing to ask for permission to conduct invasive surveillance of their customers. Organizations that are not transparent about how their systems gather data telemetry without offering shared data ownership risk product rejection, regu...
CI/CD is conceptually straightforward, yet often technically intricate to implement since it requires time and opportunities to develop intimate understanding on not only DevOps processes and operations, but likely product integrations with multiple platforms. This session intends to bridge the gap by offering an intense learning experience while witnessing the processes and operations to build from zero to a simple, yet functional CI/CD pipeline integrated with Jenkins, Github, Docker and Azure...
René Bostic is the Technical VP of the IBM Cloud Unit in North America. Enjoying her career with IBM during the modern millennial technological era, she is an expert in cloud computing, DevOps and emerging cloud technologies such as Blockchain. Her strengths and core competencies include a proven record of accomplishments in consensus building at all levels to assess, plan, and implement enterprise and cloud computing solutions. René is a member of the Society of Women Engineers (SWE) and a m...
Dhiraj Sehgal works in Delphix's product and solution organization. His focus has been DevOps, DataOps, private cloud and datacenters customers, technologies and products. He has wealth of experience in cloud focused and virtualized technologies ranging from compute, networking to storage. He has spoken at Cloud Expo for last 3 years now in New York and Santa Clara.
Enterprises are striving to become digital businesses for differentiated innovation and customer-centricity. Traditionally, they focused on digitizing processes and paper workflow. To be a disruptor and compete against new players, they need to gain insight into business data and innovate at scale. Cloud and cognitive technologies can help them leverage hidden data in SAP/ERP systems to fuel their businesses to accelerate digital transformation success.
Containers and Kubernetes allow for code portability across on-premise VMs, bare metal, or multiple cloud provider environments. Yet, despite this portability promise, developers may include configuration and application definitions that constrain or even eliminate application portability. In this session we'll describe best practices for "configuration as code" in a Kubernetes environment. We will demonstrate how a properly constructed containerized app can be deployed to both Amazon and Azure ...
Poor data quality and analytics drive down business value. In fact, Gartner estimated that the average financial impact of poor data quality on organizations is $9.7 million per year. But bad data is much more than a cost center. By eroding trust in information, analytics and the business decisions based on these, it is a serious impediment to digital transformation.
Digital Transformation: Preparing Cloud & IoT Security for the Age of Artificial Intelligence. As automation and artificial intelligence (AI) power solution development and delivery, many businesses need to build backend cloud capabilities. Well-poised organizations, marketing smart devices with AI and BlockChain capabilities prepare to refine compliance and regulatory capabilities in 2018. Volumes of health, financial, technical and privacy data, along with tightening compliance requirements by...
Predicting the future has never been more challenging - not because of the lack of data but because of the flood of ungoverned and risk laden information. Microsoft states that 2.5 exabytes of data are created every day. Expectations and reliance on data are being pushed to the limits, as demands around hybrid options continue to grow.